A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 10, Issue 2, 2011, Pages 85-96

  Kummar, Shivaani ^a,b   Sitki Copur, M ^c   Rose, Michal ^a   Wadler, Scott ^d   Stephenson, Joe ^e   O'Rourke, Mark ^f   Brenckman, Wayne ^f   Tilton, Robert ^f   Liu, Shwu Huey ^f   Jiang, Zaoli ^f   Su, Tahmun ^f   Cheng, Yung Chi ^a   Chu, Edward ^a,g  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c Saint Francis Medical Center Grand Island   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e Cancer Centers of the Carolinas   (United States)

^f Phytoceutica   (United States)

^g UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Chinese herbal medicine; Irinotecan; Metastatic colorectal cancer; Modulator of toxicity; PHY906; Side effects

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALBIFLORIN; BAICALEIN; BAICALIN; CHINESE DRUG; DEXAMETHASONE; DOLANSETRON; FLUOROURACIL; FOLINIC ACID; GLYCYRRHIZIC ACID; GRANISETRON; IRINOTECAN; LIQUIRTIN; LOPERAMIDE; ONDANSETRON; PAEONIFLORIN; PHY 906; PLACEBO; PROCHLORPERAZINE; SCUTELLARIN; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG; WOGONIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CHINESE MEDICINE; CLINICAL ASSESSMENT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; ELECTROSPRAY; FATIGUE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOKALEMIA; IN VIVO STUDY; INOCULATION; LABORATORY DIAGNOSIS; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MONOTHERAPY; MOUSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; STANDARDIZATION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT REFUSAL; TREATMENT RESPONSE; TUMOR CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT; VOMITING; WEIGHT REDUCTION;

EID: 79959336608     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2011.03.003     Document Type: Article

References (26)

1. Papac RJ. Origins of cancer therapy. Yale J Biol Med 2001; 74:391-8. (Pubitemid 34205649)
2. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998; 280:1569-75.
3. Richardson MA, Sanders T, Palmer JL, et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000; 18:2505-14. (Pubitemid 30432515)
4. Sparber A, Wootton JC. Surveys of complementary and alternative medicine: Part II. Use of alternative and complementary cancer therapies. J Altern Complement Med 2001; 7:281-7. (Pubitemid 32574902)
5. Penson RT, Castro CM, Seiden MV, et al. Complementary, alternative, integrative, or unconventional medicine? Oncologist 2001; 6:463-73.
6. Tascilar M, de Jong FA, Verweij J, Mathijssen RH. Complementary and alternative medicine during cancer treatment: beyond innocence. Oncologist 2006; 11:732-41. (Pubitemid 44157561)
7. Wong R, Sagar CM, Sagar SM. Integration of Chinese medicine into supportive cancer care: a modern role for an ancient tradition. Cancer Treat Rev 2001; 27:235-46. (Pubitemid 32851176)
8. Tang W, Eisenbrand G. Chinese drugs of plant origin: chemistry, pharmacology and use in traditional and modern medicine. 1st ed. New York: Springer-Verlag Press; 1992.
9. Vickers A. Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials. Cancer Invest 2002; 20:1069-79. (Pubitemid 35315943)
10. Okada F. Kampo medicine, a source of drugs waiting to be exploited. Lancet 1996; 348:5-6. (Pubitemid 26237236)
11. Mori K, Machida S, Yoshida T, et al. Usefulness of Kampo medicine (hangeshashin- To) in the prevention of irinotecan-induced diarrhea in advanced non-small cell lung cancer. Proc Soc Clin Oncol 1999; 14 (abstract 1996)
12. Liu S, Zaoli J, Cheng YC. Botanical activity relationship in traditional Chinese medicine: studies of PHY906 as an adjuvant therapy with cancer chemotherapeutic agents. Proc Am Assoc Cancer Res 2002; 43:961 (abstract 4758).
13. Ye M, Liu SH, Jiang Z, et al. Liquid chromatography/mass spectrometry analysis of PHY906, a Chinese medicine formulation for cancer therapy. Rapid Commun Mass Spectrom 2007; 21:3593-607. (Pubitemid 350124627)
14. Cunningham D, Pyrhönen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413-8. (Pubitemid 28510874)
15. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352:1407-12. (Pubitemid 28510873)
16. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-14.
17. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355:1041-7. (Pubitemid 30162806)
18. Meijerman I, Beijnen JH, Schelens JH. Herb-drug interactions in oncology: focus on mechanism of induction. Oncologist 2006; 11:742-52. (Pubitemid 44157562)
19. Di Ym, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John's wort and implications in drug development. Curr Pharm Des 2008; 14:1723-42. (Pubitemid 351998596)
20. Zhou SF, Lai X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr Drug Metab 2008; 9:394-409. (Pubitemid 352025194)
21. Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94:1247-9. (Pubitemid 34993875)
22. Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 341:387-91. (Pubitemid 23048140)
23. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342: 1686-92. (Pubitemid 30354515)
24. Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000; 18: 3595-603.
25. Sovak M, Seligson AL, Konas M, et al. Herbal composition PC-SPES for management of prostate cancer: identification of active principles. J Natl Cancer Inst 2002; 94:1275-81.
26. White J. PC-SPES-a lesson for future dietary supplement research. J Natl Cancer Inst 2002; 94:1261-3.